Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
Clinical trial NCT03122223 · COMPLETED
Trial details
- NCT number
- NCT03122223
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-16
- Primary completion
- 2020-07-30
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.